Granted Patent
B2
US 12,734,166 · App. 18/531,086 · Granted Sep 15, 2026
Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies
Inventors:
James Campbell (San Jose, CA); Israel Charo (Mountain View, CA); Thomas Schall (Mountain View, CA); Rajinder Singh (Belmont, CA); Yibin Zeng (Foster City, CA); Penglie Zhang (Foster City, CA)
Assignee:
CHEMOCENTRYX, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.
Claims (8)
1 . A method of reducing the development of inflammatory bowel disease in a mammal, comprising: administering a suitable amount of a CCR9 chemokine receptor inhibitor with an anti-IL-23 or an anti-IL-23 receptor blocking antibody, wherein the CCR9 inhibitor is
or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease (CD) or ulcerative colitis (UC).
3 . The method of claim 1 , wherein the anti-IL-23 or anti-IL-23 receptor blocking antibody is risankizumab, guselkumab, ustekinumab, briakinumab, brazikumab, mirikizumab, or tildrakizumab.
4 . The method of claim 1 , wherein the CCR9 inhibitor and the anti-IL-23 or anti-IL-23 receptor blocking antibody are administered in a combination formulation.
5 . The method of claim 1 , wherein the CCR9 inhibitor and the anti-IL-23 or anti-IL-23 receptor blocking antibody are administered sequentially.
6 . The method of claim 5 , wherein the CCR9 inhibitor is administered prior to the anti-IL-23 or anti-IL-23 receptor blocking antibody.
7 . The method of claim 5 , wherein the CCR9 inhibitor is administered after administration of the anti-IL-23 or anti-IL-23 receptor blocking antibody.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 13, 2025
From: CAMPBELL, JAMES; CHARO, ISRAEL; SCHALL, THOMAS; SINGH, RAJINDER; ZENG, YIBIN; ZHANG, PENGLIE
To: CHEMOCENTRYX, INC.
Reel/Frame 072899/0788 →
ASSIGNEE'S CHANGE OF ADDRESS
Recorded Nov 13, 2025
From: CHEMOCENTRYX, INC.
To: CHEMOCENTRYX, INC.
Reel/Frame 073560/0045 →
Continuity (3)
Provisional Application
63002747
· Mar 31, 2020
References Cited (87)
US 3817837A
· Rubenstein
· 1974
[cited by applicant]
US 3850752A
· Schuurs
· 1974
[cited by applicant]
US 3939350A
· Kronick
· 1976
[cited by applicant]
US 3996345A
· Ullman
· 1976
[cited by applicant]
US 4166452A
· Generales, Jr.
· 1979
[cited by applicant]
US 4256108A
· Theeuwes
· 1981
[cited by applicant]
US 4265874A
· Bonsen
· 1981
[cited by applicant]
US 4275149A
· Litman
· 1981
[cited by applicant]
US 4277437A
· Maggio
· 1981
[cited by applicant]
US 4366241A
· Tom
· 1982
[cited by applicant]
US 5120643A
· Ching
· 1992
[cited by applicant]
US 5990479A
· Weiss
· 1999
[cited by applicant]
US 6207392B1
· Weiss
· 2001
[cited by applicant]
US 6251303B1
· Bawendi
· 2001
[cited by applicant]
US 6306610B1
· Bawendi
· 2001
[cited by applicant]
US 6312914B1
· Kardos
· 2001
[cited by applicant]
US 6319426B1
· Bawendi
· 2001
[cited by applicant]
US 6322901B1
· Bawendi
· 2001
[cited by applicant]
US 6326144B1
· Bawendi
· 2001
[cited by applicant]
US 6423551B1
· Weiss
· 2002
[cited by applicant]
US 6444143B2
· Bawendi
· 2002
[cited by applicant]
US 6451399B1
· Boyce
· 2002
[cited by applicant]
US 6939885B2
· Ungashe
· 2005
[cited by applicant]
US 8916601B2
· Chen
· 2014
[cited by applicant]
US 9133124B2
· Pennell
· 2015
[cited by applicant]
US 20090163498A1
· Ungashe
· 2009
[cited by applicant]
US 20100227902A1
· Ungashe
· 2010
[cited by applicant]
US 20130267492A1
· Ungashe
· 2013
[cited by applicant]
US 20200197386A1
· Chen
· 2020
[cited by applicant]
US 20210154292A1
· Schall
· 2021
[cited by applicant]
JP 2015517465
· 2015
[cited by applicant]
JP 2016516686
· 2016
[cited by applicant]
WO 2004046092A2
· 2004
[cited by applicant]
WO 2005116088
· 2005
[cited by applicant]
WO WO2008008374A2
· 2008
[cited by examiner]
WO 2013130811A1
· 2013
[cited by applicant]
WO 2013165791
· 2013
[cited by applicant]
WO 2014143540
· 2014
[cited by applicant]
WO 2016011208
· 2016
[cited by applicant]
WO 2016057424A1
· 2016
[cited by applicant]
WO 2018219559A1
· 2018
[cited by applicant]
WO 2021102302A1
· 2021
[cited by applicant]
Rutgeerts et al., Gastroenterology, vol. 136, pp. 1182-1197 (Year: 2009).
[cited by examiner]
Zeng et al. Frontiers in Genetics, 2018, vol. 10, No. 1017, pp. 1-17.
[cited by examiner]
Ramos et al., “Targeting Specific Immunologic Pathways in Crohn's Disease”, Gastronenterol Clin N Am 36, (2017), pp. 577-588.
[cited by applicant]
Argollo et al., “Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?” Current Pharmaceutical Design, vol. 25: pp. 25-31 (2019).
[cited by applicant]
Best et al., “Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study,” Gastroenterology, vol. 70(3), pp. 439-444 (1976).
[cited by applicant]
Cayatte et al., “Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease,” Clin. Transl. Gastroenterol., vol. 3, e10, pp. 1-10 (2012).
[cited by applicant]
Davis et al., “Production of Human Antibodies from Transgenic Mice,” in Lo, ed. “Antibody Engineering: Methods and Protocols,” Humana Press, NJ, pp. 191-200 (2003).
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority dated Aug. 4, 2021, for Int'l Appln. No. PCT/US2021/025171, filed Mar. 31, 2021 (14 pages).
[cited by applicant]
International Search Report dated Aug. 4, 2021, for Int'l Appln. No. PCT/US2021/025171, filed Mar. 31, 2021 (5 pages).
[cited by applicant]
Kornbluth et al., “Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee,” Am. J. Gastroenterol., vol. 99(7), pp. 1371-1385 (2004).
[cited by applicant]
Larrick et al., “Polymerase Chain Reaction using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes from Single Hybridoma Cells”, Biotechnol., vol. 7, pp. 934-938 (1989).
[cited by applicant]
Lichtenstein et al., “ACG Practice Guidelines: Management of Crohn's Disease in Adults,” Am. J. Gastroenterol., vol. 104(2), pp. 465-483 (2009).
[cited by applicant]
Liu et al., “Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells”, Proc. Natl. Acad. Sci. USA, vol. 84 (10), pp. 3439-3443 (1987).
[cited by applicant]
Ma et al., “Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort,” Ailment Pharmacol. Ther., vol. 45: pp. 1232-1243 (20…
[cited by applicant]
Oppmann et al., “Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12”, Immunity, vol. 13 (5), pp. 715-725 (2000).
[cited by applicant]
Pedersen et al., “Inflammatory pathways of importance for management of inflammatory bowel disease,” World J. Gastroenterol., vol. 20(1): 64-77 (2014).
[cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy”, Nature, vol. 332 (6162), pp. 323-327 (1988).
[cited by applicant]
Rutgeerts et al., “Biological Therapies for Inflammatory Bowel Diseases,” Gastroenterology, vol. 136, pp. 1182-1197 (2009).
[cited by applicant]
Rutgeerts et al., “Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis,” N. Engl. J. Med., vol. 353, pp. 2462-2476 (2005).
[cited by applicant]
Schroeder et al., “A recombinant bispecific single chain antibody CD19xCD3 induces rapid and high lymphoma directed T cell cytotoxicity”.
[cited by applicant]
Schröeder et al., “Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study,” N Engl J Med., vol. 317 (26), pp. 1625-1629 (1987).
[cited by applicant]
Winter et al., “Humanized Antibodies,” TIPS, vol. 14, pp. 139-143 (1993).
[cited by applicant]
Bloemendaal et al., “TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism,” Journal of Crohn's and Colitis, vol. 12(9), pp. 1122-1130 (2018).
[cited by applicant]
Kalindjian, S.B., et al., “A New Series of Orally Bioavailable Chemokine Receptor 9 (CCR9) Antagonists; Possible Agents for the Treatment of Inflammatory Bowel Disease,” J. Med. Chem. 59(7):3098-3111 (2016).
[cited by applicant]
Li et al., “Research progress of Th17 cells and IL-23 in inflammatory bowel disease,” Chin. J. Gastroenterol. Hepatol., vol. 21(2), pp. 118-122 (2012).
[cited by applicant]
Argollo et al., “Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?”, Current Pharmaceutical Design, vol. 25(1), pp. 7-12(2019).
[cited by applicant]